Last lecture LASA

Overview of Medication Errors Due to Confusing Drug Names
- Confusing drug names are a leading cause of medication errors and pose widespread concerns globally.
- Tens of thousands of drugs are available on the market, significantly increasing the risk for errors associated with similar-sounding or similar-looking names.
Factors Contributing to Confusion
- Types of Names: Both nonproprietary names (generic) and proprietary names (brand or trademarked) can be sources of confusion.
- Similar Characteristics: Many drug names may look or sound alike.
- External Contributing Factors: Factors such as:
- Illegible handwriting
- Incomplete knowledge of drug names
- New drug offerings
- Similar packaging
- Clinical usage similarities
- Same strengths and dosage forms
- Similarity in administration frequency
- Lack of rigorous risk assessments by manufacturers and regulatory authorities.

Reported Confusion Examples in Various Countries

The following examples reflect pairs of drugs with potentially confusing names in selected countries:

Country	Brand Name (Nonproprietary name)	Brand Name (Nonproprietary name)
Australia	Avanza (mirtazapine)	Avandia (rosiglitazone)
Brazil	Losec (omeprazole)	Lasix (furosemide)
Canada	Celebrex (celecoxib)	Cerebyx (fosphenytoin)
France	fluoxétine	Fluvoxamine
Ireland	Losec (omeprazole)	Lasix (furosemide)
Italy	Diamox (acetazolamide)	Zimox (amoxicillina triidrato)
Japan	Almarl (arotinolol)	Amaryl (glimepiride)
Spain	Dianben (metformin)	Diovan (valsartan)
Sweden	Avastin (bevacizumab)	Avaxim (hepatitis A vaccine)

International Naming Conventions
- The World Health Organization’s International Nonproprietary Names Expert Group aims to develop accepted names for pharmaceutical substances globally.
- Brand names differ significantly between regions, and the same medicine might have varied active ingredients across countries. Brands with identical or phonetically similar names might contain distinct active ingredients, leading to potential confusion.
Regulatory Authority Approvals
- Regulatory bodies (e.g., FDA, European Union bodies) approve trademark names after assessing confusion potential with existing drugs. Despite rigorous protocols, similar-sounding names continue to be approved.
Research Needs
- More research is essential for developing strategies to ensure drug names cannot be confused with one another.

Legibility and Clarity of Prescriptions
- Enhance prescription legibility through better handwriting practices, use of pre-printed order forms, or electronic prescribing methods.
- Write both brand and nonproprietary names, dosage form, strength, directions, and indications clearly in prescriptions.
- Enforce read-back procedures for oral orders to confirm message accuracy.
Reducing Look-Alike, Sound-Alike Confusion
- Conduct periodic analyses of new product names to identify potential hazards.
- Physically separate medicines with LASA names in distribution areas, differentiating them visually where possible.
- Use “tall man” lettering (e.g., DOPamine versus DoBUTamine) in documentation to clarify drug name differences.
Education and Training
- Provide training for healthcare professionals on LASA medications to address the risk of medication errors.
- Emphasize the need for awareness of LASA complications during professional development.

Risk Management
- Organizations should conduct an annual review of medications to identify and manage LASA risks.
Clinical Protocols
- Establish protocols that minimize verbal and telephone orders to reduce communication errors.
- Ensure labels are clearly read prior to medication administration instead of depending solely on visual cues.
Patient and Caregiver Involvement
- Engage patients and caregivers in risk assessments by providing accessible medication information.
- Review dispensed medications with patients for understanding.

Technology Considerations
- Monitor risks associated with technologies intended to minimize medication errors (e.g., computerized physician order entry - CPOE).
- Incorporate alerts for name confusion in CPOE systems.

Grounded in expert opinion and consensus, applicable in various regulatory settings and pharmaceutical organizations.

Empowering Patients
- Advise, instruct, and sensitize patients on LASA medication risks and how to identify them.
- Instruct patients to notify caregivers if medications appear different from their usual ones.
Utilizing Community Pharmacies
- Encourage interaction with community pharmacies for further insights into LASA medication issues.

Continued marketing of LASA drugs, resistance from prescribers, lack of standardization in educational campaigns, regulatory variances, and resource constraints might impede progress.

Potential increased costs due to the push for brand names over nonproprietary names, and the possibility of patients receiving lower-quality medications under generic labels could arise.

Lambert BL et al. Similarity as a risk factor in drug-name confusion errors. Medical Care, 1999, 37(12):1214–1225.
McCoy LK. Look-alike, sound-alike drugs review: include look-alike packaging as an additional safety check. Joint Commission Journal on Quality and Patient Safety, 2005, 31(1):47–53.
Hoffman JM, Proulx SM. Medication errors caused by drug name confusion. Drug Safety, 2003, 26:445–452.
Drug name confusion: preventing medication errors. FDA Consumer Magazine, July–August 2005, 39(4).
ISMP’s list of confused drug names. Institute for Safe Medication Practices, April 2005.
Look-alike and sound-alike drug names—a step forward. Hospital News, January 2004.
Look-alike, sound-alike drug names. Sentinel Event Alert, Issue 19, May 2001.
2006 National Patient Safety Goals. The Joint Commission, 2006.
Davis NM, Cohen MR, Teplitsky B. Look-alike and sound-alike drug names: the problem and the solution. Hospital Pharmacy, 1992.
Filik R et al. Evaluating the effectiveness of capital ("Tall Man") letters using eye movement data. Social Science & Medicine, 2004.